financetom
Market
financetom
/
Market
/
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Jun 25, 2024 6:12 AM

The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Pacific Health Care Organization

The Trade: Pacific Health Care Organization, Inc. ( PFHO ) CEO and President Tom Kubota bought a total of 6,270 shares at an average price of $0.88. To acquire these shares, it cost around $5,543.

What's Happening: The company reported net income of $176,427 or $0.01 per share for the three months ended June 30, 2023.

What Pacific Health Care Organization Does: Pacific Health Care Organization Inc ( PFHO ) is a specialty workers’ compensation managed care company.

System1

The Trade: System1, Inc. ( SST ) 10% owner Cee Holdings Trust acquired a total of 8,013 shares at an average price of $1.44. To acquire these shares, it cost around $11,575.

What's Happening: On May 9, System1 posted upbeat first-quarter results.

What System1 Does: System1 Inc ( SST ) develops technology and data science to operate a responsive acquisition marketing platform.

Gossamer Bio

The Trade: Gossamer Bio, Inc. ( GOSS ) President and CEO Faheem Hasnain acquired a total of 372,000 shares at an average price of $0.67. The insider spent around $250,282 to buy those shares.

What's Happening: On June 25, Oppenheimer analyst Andreas Argyrides initiated coverage on Gossamer Bio ( GOSS ) with an Outperform rating and announced a price target of $9.

What Gossamer Bio Does: Gossamer Bio Inc ( GOSS ) is a clinical-stage biopharmaceutical company.

Read More: Stocks To Watch On Tuesday: Boeing, FedEx And More

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nasdaq quarterly profit rises as trading volumes surge
Nasdaq quarterly profit rises as trading volumes surge
Oct 21, 2025
(Reuters) -Nasdaq's profit rose in the third quarter, the exchange operator said on Tuesday, as persistent market volatility from macroeconomic and U.S. policy uncertainty boosted trading volumes. Traders actively shuffled their portfolios to navigate the Trump administration's uncertain trade policies and growth concerns, boosting volumes for the exchange's U.S. equity options contracts, as well as cash equities. The company's market...
US STOCKS-Wall Street futures subdued as earnings season gains momentum
US STOCKS-Wall Street futures subdued as earnings season gains momentum
Oct 21, 2025
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) * Futures flat: Dow up 0.03%, S&P 500 up 0.03%, Nasdaq down 0.02% * Fluor gains after reports Starboard has taken nearly 5% stake * Health insurers rise after upbeat results from Elevance (Updates prices) By Pranav Kashyap and...
Stocks Down Pre-Bell as Traders Digest US-Australia Critical Minerals Deal, Await Latest Earnings
Stocks Down Pre-Bell as Traders Digest US-Australia Critical Minerals Deal, Await Latest Earnings
Oct 21, 2025
07:26 AM EDT, 10/21/2025 (MT Newswires) -- US equity futures were pointing lower on Tuesday as investors assess the critical minerals deal between the US and Australia and await the next wave of corporate earnings. The S&P 500, the Dow Jones Industrial Average and the Nasdaq edged down 0.1% each in premarket activity. The indexes finished Monday in the green...
XORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct Offering
XORTX Therapeutics Down Near 10% In US Premarket As Prices US$1.1 Million Registered Direct Offering
Oct 21, 2025
08:13 AM EDT, 10/21/2025 (MT Newswires) -- XORTX Therapeutics ( XRTX ) , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, was down near 10% in US premarket after announcing Tuesday that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved